steadi growth initi buy
earli combin covidien emerg world
largest medic technolog servic solut provid compani
domin player segment particip
revenu year introduc
consist steadi flow new technolog though sever recent
anticip product pipelin includ hugo new robot system
could meaning impact acceler revenu growth
point support thesi
transform launch led particularli impress roll-out new
product continu flow separ
robot mdt pipelin includ launch new next-gener
across platform within larg high growth market tavr
diabet snm
robot system use spine surgeri market made
substanti invest hold consider share acquir expertis
pair proven track record navig enabl technolog
imag posit success launch next
robot system hugo hugo target soft tissu surgeri field
current own rare one product move
needl compani like simpli given size revenu base
though think hugo potenti
top-lin growth drive flow fulli expect compani
continu invest organ inorgan opportun
invest translat sustain top-lin growth consider
valuat risk
price target appli price-to-earnings multipl adjust ep
risk includ slowdown core market competit core market
key product launch unsuccess inabl execut revenu
margin goal
tr target
initi buy pt
page
appli price-to-earnings multipl discount median med-tech larg cap peer group ep estim deriv
pt buy-rat share
unexpect slowdown core end market includ cardio spine neuro surgic neg impact weighted-
averag market growth rate compani revenu growth
competit core end market either larg establish healthcar compani new smaller competit
entrant differenti technolog impact abil regain market share price pressur
product launch includ hugo robot system delay gain traction market
inabl execut target top-lin margin expans goal
page
scenariobear casestrhbul bp lower earn growth vs base case multipl contract current levelsassum msd revenu growth acceler current level earn growth compound-annual-growth-rate hsd multipl expand current level assum bp higher earn growth vs base case multipl expand current levelsupsid vs current plc
industri leader medic devic space pioneer innov numer
market sinc found broad portfolio product divid four busi segment
cardiac vascular group cvg includ implant af ablat valv stent graft
gastrointestin endoscopi product airway ventil product renal patient monitor
restor therapi group rtg includ wide varieti product use brain
neurovascular brain modul neurosurgeri product specialti ent pelvic
health product pain spinal cord stimul implant drug infus nerv
ablat well spine biolog spacer implant fixat system graft
diabet includ insulin pump continu glucos monitor
fy sale segment
littl less half
medtron revenu
gener outsid
unit state
presenc approxim
page
expand
becom
devic compani
expand
world
found
develop first
spinal
invest
launch
pacemak
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
want robot oper room robot work conjunct surgeon oper room design intent
improv outcom beyond physic human alon could offer case miniatur effector attach robot arm
go human hand perform minim invas procedur proven reduc risk patient faster recoveri time
import patient hospit current robot market perform wide array surgic applic includ
ortho spine gener surgeri gynecolog urolog sever
arent robot expens ye cost one major barrier broader adopt time regard up-front capit
invest well cost per procedur current intuit surgic main player robot soft tissu surgeri three variat da
vinci robot da vinci da vinci xi da vinci sp market capit unit cost rang second major cost
compon cost per procedur current significantli higher establish minim invas procedur believ increas
competit new player enter market well help hospitals/surgeon overcom barrier drive low util current instal base
execut less surgeri per day soft tissu robot increas surgeon train could help lower cost lastli invest
robot help establish hospit reput surgic area turn help attract patient surgic talent center fuel
wrap decad compound-annual-growth-rate
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
want robot oper room robot work conjunct surgeon oper room design intent
improv outcom beyond physic human alon could offer case miniatur effector attach robot arm
go human hand perform minim invas procedur proven reduc risk patient faster recoveri time
import patient hospit current robot market perform wide array surgic applic includ
ortho spine gener surgeri gynecolog urolog sever
arent robot expens ye cost one major barrier broader adopt time regard up-front capit
invest well cost per procedur current intuit surgic main player robot soft tissu surgeri three variat da
vinci robot da vinci da vinci xi da vinci sp market capit unit cost rang second major cost
compon cost per procedur current significantli higher establish minim invas procedur believ increas
competit new player enter market well help hospitals/surgeon overcom barrier drive low util current instal base
execut less surgeri per day soft tissu robot increas surgeon train could help lower cost lastli invest
robot help establish hospit reput surgic area turn help attract patient surgic talent center fuel
wrap decad compound-annual-growth-rate
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
current experi robot
medtron first foray robot though partnership mazor compani
pioneer first robot system spine surgeri
first invest mazor partnership develop maxor
legaci gener mazor renaiss approv spinal surgeri sinc
partnership launch mazor gone well rel histor launch
robot underscor support robot spine healthcar commun
acknowledg mazor renaiss intutit surgic da vinci first
market thu prove action speak mazor launch took
month place unit less half time intuit roughli fourth
time mazor renaiss
launch mazor proven abil innov around system
integr expertis navig imag mazor stealth launch unit
state januari two month fda approv system pair tradit
mazor medtron stealthstat navig ad degre freedom
depth screw real-tim reconcili rel surgic plan two unit
compat o-arm imag system provid visibl surgic
feedback within investor event septemb medtron
announc accumul mazor stealth case thu far across
 hospit total placement unit mazor launch
late mazor stealth rise instal base inclus
focus surgic synergi strategi offer fully-integr procedur
solut spine implant navig intra-op imag surgic plan
execut confirm pay seen recent rtg growth think
extend lesson learn surgic synergi strategi gener
surgeri market launch hugo
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
soft tissu market procedur basi even bigger robot offer similar benefit soft tissu space spine includ
fewer complic shorter hospit stay overal faster recoveri translat less cost system
current surgeon train exist instal base soft tissu robot around world util remain low less
procedur per day across unit place global basi estim robot assist surgeri market arena
million plu surgeri year grow mid-to-upp teen open surgeri provid greatest risk longest
recoveri patient still repres global procedur
market today million surgeri annual accord manag
procedur
procedur
procedur
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
hugo septemb unveil first soft-tissu robotic-assist surgeri ra program dub hugo hugo
modular platform design allow mobil oper room surgic arm individu unit allow greater util within
hospit surgeri requir four arm allow machin roll oper room increas optim surgic tower
univers tower allow use laparoscop robot case tower sold medtron gener capabl
power devic robot laparoscop open surgeri visual system power storz also use mode
common laparoscop procedur one featur highlight upgrad product hospit
area consider develop process
import hugo expect ra major driver growth within mitg capit equip sale well pull-
surgic input stapl hugo compet davinci system two decad success
market weve observ strong reput qualiti skill machin nonetheless except histori
come technolog strong long-stand relationship medic commun capabl balanc sheet ensur success ra
current train surgeon surgic product annual estim surgeon around world alreadi
train ra
strong foothold within medic commun high usag
respect surgic instrument gener surgeri think integr
medtron exist surgic tool robot allow surgeon continu use
product familiar like stock shelv today reduc one
potenti barrier introduct also think medtron stand relationship
valu access committe experi capit sale help grow
timelin placement ou addit clinic data gather follow expect
begin back half calendar goal ce mark submiss
calendar file calendar current
increment top-line growth mitg outlin call less basi
point bp bp street current
estim mid-singl digit overal revenu growth next sever year ra
contribut could meaning
follow similar slightli acceler cadenc intuit earli day
averag sale price per unit could see lift mitg segment
base unit shipment alon
hugo first introduc sept
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
depart ceo omar describ current pipelin strongest compani histori beyond ra platform mitg
launch launch multipl import product year fiscal impress pipelin ahead across
remaind portfolio cvg rtg diabet
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
line-up cardiac vascular group
evolut-pro tavr tavr transcathet aortic valv replac fast grow market import one sale
leap overal back fda august decis allow expans low risk market evolut-
pro launch second quarter fiscal earli driven acceler number procedur implant
linq reveal linq wireless implant cardiac monitor record subcutan electrocardiogram patient requir long-term
monitor and/or on-going manag version first waferscale-bas devic insert loop monitor area offer five
year batteri two year beyond current gener bluetooth connect addit sensor
micra av micra av leadless catheter-impl pacemak expand current micra tp offer patient atrioventricular
block normal sinu rhythm data support studi marvel publish journal american colleg cardiolog
novemb subsequ submiss micra av approv fda current micra unit share singl chamber pacemak
market accord product could meaning new indic expand micra particip
bradycardia market expect micra av becom avail
launch drive current growth
micra vr
size
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
pipelin diabet
diabet high-growth segment constant currenc fairli small portion overal revenu
revenu fiscal
minim drove growth fiscal though pressur competit offer build-up anticip
upcom launch howev drive strong growth intern launch demonstr demand
ahead minim roll pathway allow patient either warranti new therapi
purchas minim switch upon avail addit charg minim hybrid close loop system bluetooth
design take step autom correct bolus base sensor read goal increas time-in-rang
current minim system averag time auto mode near vs trial enrol product began june
includ adult pediatr patient pivot data expect present attd confer februari approv slate
guardian sensor non-adjunct juli file pma approv fda non-adjunct label guardian sensor
expect approv sometim earli mid winter label could open medicar market current requir non-adjunct product
leadership invest
given high growth seen diabet taken appropri step
solidifi posit market leader segment octob sean salmon
assum leadership divis come posit svp coronari
structur heart divis within cvg addit announc mid-decemb
acquisit behavior-track softwar compani name klue
technolog intend incorpor person close loop pcl insulin
pump system system current develop receiv breakthrough
devic design back februari expect launch sometim next
month time-in-rang improv upon launch goal
klue acquisit one layer dedic space novemb
also acquir isra nutrit data start-up nutrino health
also partner nonprofit tidepool develop interoper autom
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
pipelin restor therapi group
weve alreadi discuss implic mazor spine brain therapi divis within rtg addit
pipelin offer pelvic specialti therapi
sacral neuromodul snm enhanc interstim micro interstim ii surescan lead
estim gener snm sale interstim ii surescan lead enhanc legaci
offer addit full bodi mri compat interstim micro intend first recharg offer significantli
smaller size vs interstim ii axon r-snm therapi feel degre interstim micro concept
come respons competitor entranc think expans offer across patient profil well leverag current portfolio
advanc technolog product enhanc use surescan lead welcom patient doctor alik market
forecast doubl next five year
addit product launch within rtg includ next-gener intraop nerv monitor system nim vital percept pc deep brain stimul
incorpor new technolog allow record brain signal data implant lead offer patient tailor therapi catalyst includ
unveil next-gener nan
line commun open recent begun regular call seri investor leadership within product divis offer
deeper vantag point reinvigor effort product pipelin appreci commun add confid
taken necessari step candidli review market posit humbl accept shortcom tact strateg execut instat
bottom line listen research market end posit refresh innov pipelin
strateg plan commun investor-focus manag team chang tune like sound
page
matter stock item alloc cash flow
strh thought fuel growth innov tuck-in maxim sharehold valu
fire cylind front-end capit alloc strategi steal limelight
manag annual incent plan tie directli tie valu creation annual incent plan includ equal weight target mirror
initi guidanc revenu growth non-gaap dilut ep exceed beat initi guidanc across board
sale vs guid ep vs guid convers vs guid far anoth stori
beat rais except diabet slightli softer expect
long-term perform ltpp measur target achiev
well align view summar tabl right think three goal
attain forecast top-line growth
forecast believ compani continu
deploy share repurchas dividend maintain target dividend
pay-out ratio minimum return sharehold
ultim innov experienc well align manag
team rate buy pt
return sharehold past
continu grow dividend base
div
share repurcha
page
select member mdt leadership
omar ishrak serv ceo chairman
board sinc june mr ishrak retir
ceo april announc
august mr ishrak becom execut
chairman follow retir continu
chairman board
mr ishrak focus three core strategi sinc
join compani includ therapi innov
econom valu global mr ishrak
engin acquisit covidien billion global
manufactur surgic product suppli prior
mr ishrak spent year ge
held sever leadership role recent presid
ceo ge healthcar system
evp presid cardiac
vascular group
michael coyl serv execut vice presid
presid medtron cardiac vascular group
sinc join compani decemb mr coyl
overse four busi divis
respons provid strateg direct ensur
align integr growth plan cross-funct
prior join mr coyl provid leadership
consult servic privat equiti ventur capit
geoffrey martha appoint presid
novemb assum role
ceo follow mr ishrak retir april
prior role mr martha held sever leadership
role recent execut vice
presid presid restor
therapi group rtg respons
therapi specialti therapi spine
mr martha led acquisit covidien
name chief integr offic juli
lead integr covidien prior
mr martha spent year ge
held sever execut role recent
manag director busi develop ge
evp presid minim
bob white serv execut vice presid
presid minim invas group sinc
decemb prior role mr white serv
senior vice presid presid medtron asia
pacif becam fastest grow region within
mr white led integr
covidien across australia new
south korea
prior mr white held sever leadership
posit covidien
annual perform bonu determin
annual incent plan includ equal weight target
mirror initi guidanc revenu growth non-gaap
dilut ep
vice-president hires/departur captur linkedin last month
evp cfo
karen parkhil serv execut vice presid
cfo sinc join compani june
current role ms parkhil lead
medtron global financ organ respons
key support function includ treasuri
busi develop corpor strategi
prior ms parkhil serv vice
chairman cfo five year
evp presid
brett wall appoint execut vice presid
presid restor therapi
group rtg novemb current role mr
wall respons
strateg direct oper manag rtg
specialti therapi spine
prior acquisit covidien mr wall
serv presid neurovascular
covidien manag commerci activ
function busi result doubl revenu
tenur
evp presid diabet
sean salmon appoint execut vice presid
presid medtron diabet group octob
compani sinc
current role mr salmon respons overal
strateg direct busi prior role mr
salmon held sever leadership role
recent presid coronari structur heart
within cardiac vascular group
mr salmon close year experi
medic devic pharmaceut industri held
previou role cr bard johnson johnson
surgivis eurorscg life
vice-president educ train
region vice-president sale
current vice-president sale conventu
page
compani report strh estim
page
period million oper expens incom excl non-oper net incom ex ni ex attribut plc
compani report strh estim
page
period million receiv less current total current properti plant intang asset intang asset sharehold equityshort-term payabl expens total current tax long-term total equitycommon paid-in non-own total sharehold liabil sharehold plc
compani report strh estim
page
period million provid oper activ net incom chargesstock benefit payabl accru op asset -- oper activ acquisit net cash acq invest use invest decreas decreas lt common tax benefit stock base common stock warrant -- financ exchang rate chang increas decreas equival beg equival end plc
industri leader medic devic space pioneer innov numer
market sinc found broad portfolio product divid four busi
segment cardiac vascular group minim invas therapi group restor therapi
earli compani combin covidien emerg world largest medic
technolog servic solut provid gener revenu though
point along way unfortun common matur corpor think
compani simpli grew comfort market posit howev siren sound
competitor emerg new differenti technolog appear woken
rapidli reinvigor current portfolio offer pursu attract high growth
market robot innov re-establish
forefront med tech innov rate share buy
valuat risk
appli price-to-earnings multipl discount median med-tech larg cap peer group
ep estim deriv pt
risk price target valuat includ competit core end market either larg
establish healthcar compani new smaller competit entrant differenti technolog
impact abil regain market share lead price pressur snm market continu
develop expect due inabl chang physician mindset and/or influenc patient behavior
unforeseen challeng product launch includ next gener system
delay and/or gain traction expect commerci misstep compani grow
sale forc clinic specialist team rapid pace pend patent litig medtron
creat nois market requir increas spend ultim lead unfavor outcom
lack profit liquid risk
kaila krum herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
